Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

Phase 4 Not yet recruiting 140 enrolled Tuen Mun Hospital

RandomizedParallel-groupTriple-blindPrevention

Summary

A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies

Timeline

Start: 2025-01
Primary completion: 2025-12
Completion: 2026-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E	Vaccine	—	—

Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

Summary

Timeline

Drugs

Indications